AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 4 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Co. was sued June 4, 2002, by 29 states that said the drug maker acted illegally to maintain its monopoly on the cancer-fighting drug Taxol and keep cheaper generic versions off the market.
The lawsuit alleges that Bristol-Myers fraudulently obtained patents that had no legal validity for Taxol, one of the most widely used treatments for breast and ovarian cancer.
Ohio was the lead plaintiff on the lawsuit, which said the company's actions delayed generic versions of Taxol from entering the market by at least 30 months. That forced hospitals, cancer patients and states to pay almost 30% more for Taxol treatments, the lawsuit said.
Taxol treatments generally cost $6,000-$10,000 per patient. The states are seeking unspecified damages.
"These marketplace practices have had a dramatic impact on the ability of people and health care systems to obtain affordable, effective drugs," said Ohio Attorney General Betty Montgomery.
Taxol has always been an especially contentious issue for consumer groups because it was discovered by the taxpayer-funded National Cancer Institute, which licensed the drug to Bristol-Myers. First approved in 1992 as second-line therapy for advanced ovarian or breast cancer, Taxol is now also used against AIDS-related Kaposi's sarcoma and lung cancer.
Robert Laverty, a Bristol-Myers spokesman, said the states were merely joining ongoing litigation brought by generic drug makers.
Source: HighBeam Research, Twenty-nine states file suit against drug maker Bristol-Myers...